# A Study of Lumigan® 0.01% in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

> **NCT01589510** · — · COMPLETED · sponsor: **Allergan** · enrollment: 419 (actual)

## Conditions studied

- Glaucoma, Open-Angle
- Ocular Hypertension

## Interventions

- **DRUG:** bimatoprost 0.01% ophthalmic solution

## Key facts

- **NCT ID:** NCT01589510
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2013-02
- **Final completion:** 2013-02
- **Target enrollment:** 419 (ACTUAL)
- **Last updated:** 2014-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01589510

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01589510, "A Study of Lumigan® 0.01% in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01589510. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*